The Risk of Relationship between Hormonal Replacement Therapy and Cancer

Thiele Osvaldt Rosales; Iara Patrícia Albrecht; Guilherme Barroso Langoni de Freitas

doi:doi:10.11648/j.crj.s.2014020601.16

| Peer-Reviewed

The Risk of Relationship between Hormonal Replacement Therapy and Cancer

Thiele Osvaldt Rosales, Iara Patrícia Albrecht, Guilherme Barroso Langoni de Freitas

Published in Cancer Research Journal (Volume 2, Issue 6-1)

Received: 10 December 2014 Accepted: 13 December 2014 Published: 27 January 2015

Views: Downloads:

Download PDF

Share This Article

Twitter
Linked In
Facebook

Abstract

Menopause is an endocrine condition due to the decline in ovarian activity, which occurs in all women and is characterized as a progressive hypoestrogenism. To minimize damage from lack hormonal activity, hormone replacement therapy has been developed (TRH), which is widely used around the world, often without criteria pre-established. Thus, this study aims to identify hormonal therapies used postmenopausal and relate them to the development of tumors. In addition, identify the criteria for the use of HRT, the utilization time and women who are part of the risk groups are also objectives of this study. In the beginning, the clinical methodology of HRT included only estrogen, but epidemiological studies have observed that the progestin presence is essential in endometrial hyperplasia control adding to the therapy. Progestogens act depending on its molecular structure, and consequently selectivity, or may interact with other steroid receptors. From this interaction, different pharmacodynamic answers about importance in the development of tumors can be observed, ie, progesterone activity, estrogen, antiestrogen, androgen and / or antiandrogen. In view of the mechanism of carcinogen administration of estrogens, it can be said that HRT increases the risk of breast, uterus and ovary cancer. However, the estrogenic actions may be adjusted when there is administration of progestin drugs and with antiestrogenic and antiandrogenic actions. Given this, in menopausal women, it is advisable to trace gynecological cancer, before, during and after any therapeutic interventions, and the decision of using and the choice of HRT on an individual basis, through a careful assessment of signs and symptoms and long-term risk.

Published in	Cancer Research Journal (Volume 2, Issue 6-1) This article belongs to the Special Issue Lifestyle and Cancer Risk
DOI	10.11648/j.crj.s.2014020601.16
Page(s)	49-56
Creative Commons	This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.
Copyright	Copyright © The Author(s), 2024. Published by Science Publishing Group

Keywords

Hormonal replacement therapy, Cancer, Estrogens, Progestogen

References

[1]	Lorenzi, D. R. S., L. Catan B.,Moreira, K., Ártico, G. R. (2009) Assistência a mulher climatérica: novos paradigmas. Rev Bras Enferm 62 (2), 287-93.
[2]	Zahar S. E. V., Aldrighi, J. M. Neto A. M. P., Conde, D. M, Zahar., L. O., Russomano, F. (2005) Qualidade de vida em usuárias e não usuárias de terapia de reposição hormonal., Rev Assoc Med Bras 51 (3), 133-8
[3]	North American Menopause Society . (2004) Treatment of menopause-associated vasomotor symptoms: position statement of The North American Menopause Society. Menopause 11 (1), 11-33.
[4]	Pardini, D. (2007) Terapia hormonal da menopausa. Arq Bras Endocrinol Metab. 51 (6), 938-942.
[5]	Tang, M.X., Jacobs D., Stern,,Y, . Marder, K., Schofiel, P., Gurland, B. Andrews, H., Mayeux, R. (1996) Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease. Lancet. 348 (9025), 429-32.
[6]	Barros, I. M. L. (2010) Prevalência de aterosclerose de carótida e fatores associados em mulheres a partir do climatério. Tese. Universidade de São Paulo.
[7]	Fernandes. E. C., Pinho-Neto, J. S. L., Gebara, O. C. E. (2008) I Diretriz Brasileira sobre Prevenção de Doenças Cardiovasculares em Mulheres Climatéricas e a Influência da Terapia de Reposição Hormonal (TRH) da Sociedade Brasileira de Cardiologia (SBC) e da Associação Brasileira do Climatério (SOBRAC). Arq Bras Cardiol 91(1 supl.1), 1-23.
[8]	Lanzillotti, H. S., Lanzillotti, R. S., Trotte, A. P. R., Dias, A., Bornand, B., Costa, E. A. M. M. (2003) Osteoporose em mulheres na pós-menopausa, cálcio dietético e outros fatores de risco. Rev. Nutr., Campinas, 16 (2), 181-193.
[9]	Leal, J. H. S., Cubero, D., Giglio, A. D. (2010) Hormonioterapia paliativa em câncer de mama: aspectos práticos e revisão da literaturaa. Rev Bras Clin Med; 8 (4), 338-43.
[10]	Trindade, M. D. M., Tocci H. A. (2000) Câncer do endométrio uterino no climatério e os efeitos de hormonioterapia. Rev Enferm Unisa ; 1, 99-103.
[11]	Toledo, M. C. S. (2012) Expressão dos receptores de estrógeno, progesterona, andrógeno e her2 no câncer epitelial de ovário. Dissertação. Universidade Estadual de Campinas 58f.
[12]	Giacomini, D. R E., Mella, A. C. (2006) Reposição Hormonal: vantagens e desvantagens. Semina: Ciências Biológicas e Saúde 27 (1), 71-92.
[13]	Araújo, N. L. C. J., Athanazio, D. A. (2007) Terapia de reposição hormonal e o câncer de endométrio. Cad. Saúde Pública 23 (11), 2613-2622.
[14]	Grady, D., Gebretsadik, T., Kerlikowske, K., Ernster, V., Petitti, D. (1995) Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet Gynecol 85 (2), 304-13.
[15]	Beral, V., Bull, D., Reeves, G. (2005) Million Women Study Collaborators. Endometrial cancer and hormone-replacement therapy in the Million Women Study. Lancet. 365 (9470), 1543-51.
[16]	Shapiro, S., Kelly, J. P., Rosenberg, L., Kaufman, D. W., Helmrich, S. P., Rosenshein, N. B., Lewis, J. L. J., Knapp, R. C., Stolley, P. D., Schottenfeld, D. (1985) Risk of localized and widespread endometrial cancer in relation to recent and discontinued use of conjugated estrogens. N Engl J Med 313 (16), 969-72.
[17]	http://www.moreirajr.com.br/revistas.asp?fase=r003&id_materia=4843.
[18]	National Health and Medical Research Council (2005) Hormone replacement therapy: Exploring the options for women. 45 f.
[19]	Schierbeck L. L., et al. (2012) Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. Br Med J 345, 1-11.
[20]	http://www.mims.co.uk/Drugs/obstetrics-and-gynaecology/menopausal-disorders/
[21]	Brunton, L., Parker, K., Blumenthal, D., Buxton, I., Goodman & Gilman - Manual de farmacologia e terapêutica. Ed. Artmed. 2010.
[22]	Vigo, F., Lubianca, J. N., Corleta, H. V. E. (2011) Progestógenos: farmacologia e uso clínico. Femina 39 (3), 127-137.
[23]	Sitruk-Ware, R. (2004) New progestogens: a review of their effects in perimenopausal and postmenopausal women. Drugs Aging 21 (13), 865-83.
[24]	Sitruk-Ware, R. (2006) New progestagagens for contraceptive use. Human Reproduction Update 12 (2), 169–178.
[25]	Schindler, A. E., Campagnoli, C., Druckmann R., Huber, J., Pasqualini, J. R., Schweppe, K.W., Thijssen, J. H. (2008) Classification and pharmacology of progestins. Maturitas 61 (1-2), 171-80.
[26]	Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee. 2014.Avaiable in http://s.details.loinc.org/LOINC/10861-3.html?sections=Simple
[27]	Fabjani, G., Tong, D., Czerwenka K.., Schuster, E., Speiser, P., Leodolter, S., et al. (2002) Human progesterone receptor gene polymorphism Progins and risk for breast cancer in Austrian women. Breast Cancer Res Treat 72 (2), 131-7.
[28]	Hardman, J.G.; Limbird, L.E. Goodman & Gilman As Bases Farmacológicas da Terapêutica. McGraw Hill, 11ª ed. 2006.
[29]	Rang, H.P.; Dale, M.M.; Ritter, J.M.; Gardner, P. Farmacologia. Elsevier, 6ª ed. 2007.
[30]	Cericatto, R. (2002) Expressão gênica do receptor estrogênico-ɑ, blc-2 E c-myc em fibroadenomas e no tecido mamário normal circunjacente. Dissertação. Universidade Federal do Rio Grande do Sul.
[31]	C. E. Fernandes, J. Rennó Jr, E. A. P. Nahas, N. R. Melo, J. A. S. Ferreiras, R. B. Machado, S. Peixoto. (2006) Síndrome de insuficiência androgênica – critérios diagnósticos terapêuticos. Rev. Psiq. Clín. 33 (3), 152-161.
[32]	Management of osteoporosis in postmenopausal women: 2010 position statement of The North American Menopause Society. Menopause 17 (1), 25-54.
[33]	Pardini, D. (2014) Terapia de reposição hormonal na menopausa. Arq Bras Endocrinol Metab 58 (2), 172-181.
[34]	Fonseca, E. A. I. (2010) Influência da obesidade e da resistência à insulina sobre o desenvolvimento tumoral: Efeito da metformina. Dissertação. Universidade de São Paulo 45f.
[35]	Stocks, T., Rapp, K., Bjørge, T., Manjer, J., Ulmer, H., Selmer, R., Lukanova, A., Johansen, D., Concin, H., Tretli, S., Hallmans, G., Jonsson, H., Stattin, P. (2009) Blood Glucose and Risk of Incident and Fatal Cancer in the Metabolic Syndrome and Cancer Project (Me-Can): Analysis of Six Prospective Cohorts. PLoS Medicine 6 (12), e1000201, 1-14.
[36]	Hsing, A.W., Gao, Y-T., Chua, S., Deng, J., Stanczyk, F..Z. (2003) Insulin Resistance and Prostate Cancer Risk. Journal of the National Cancer Institute 95 (1), 67-71.
[37]	Barp, C. G., Almeida, D. J., Freitas, G. B. L. (2014) Breast cancer and postmenopausal obesity: the risk factors in this relationship. Cancer Research Journal 2 (1), 9-14 11.
[38]	Somboonporn, W., Davis, S. R. (2004) National Health and Medical Research Council. Testosterone effects on the breast: implications for testosterone therapy for women. Endocr Rev 25 (3), 374-88.
[39]	Cauley, J. A., Lucas, F. L., Kuller, L. H., Pedra, K., Browner, W., Cummings, S. R. (1999) Elevated serum estradiol and testosterone concentrations are associated with a hight risk for breast cancer. Study of Osteoporotic Fractures Research Group. Ann Intern Med 130 (4 Pt 1), 270-7.
[40]	Isotton, A. L., Wender, M. C. O., Czepielewski, M. A. (2008) Influências da reposição de estrógenos e progestágenos na ação do hormônio de crescimento em mulheres com hipopituitarismo. Arq Bras Endocrinol Metab 52 (5), 901-916.
[41]	Walsh, B.W., Schiff, I., Rosner, B., Greenberg, L., Ravnikar, V., Sacks, F. M. (1991) Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. N Engl J Med. 325(17), 1196-204.
[42]	Godsland, I. F., Gangar, K., Walton, C., Cust, M. P., Whitehead, M. I., Wynn, V., Stevenson, J. C. (1993) Insulin resistance, secretion, and elimination in postmenopausal women receiving oral or transdermal hormone replacement therapy. Metabolism 42 (7), 846–853.
[43]	Serin, I. S., Özçelik B., Başbuǧ, M., Aygen, E., Kula M., Erez, R. (2001) Long-term effects of continuous oral and transdermal estrogen replacement therapy on sex hormone binding globulin and free testosterone levels. Eur J Obstet Gynecol Reproductive 99 (2), 222-5.
[44]	Bittner, J. J. (1948) The causes and control of mammary cancer in mice. Harvey Lect 42, 221-246.
[45]	Meuten, D. J. Tumors in domestic animals. 4ª Ed. 2002. Pg 788.
[46]	Silva, A. E., Serakides, R., Cassali, G. D. (2004) Carcinogênese hormonal e neoplasias hormônio-dependentes. Ciência Rural 34 (2), 625-633.
[47]	Henderson, B. E., Feigelson, H. S. (2000) Hormonal carcinogenesis. Carcinogenesis 21 (3), 427-433.
[48]	Wigertz, A., Lönn , S., Mathiesen, T., Ahlbom, A., Salão, P., Feychting, M., Swedish Interphone Study Group. (2006) Risk of brain tumors associated with exposure to exogenous female sex hormones. Am J Epidemiol 164 (7), 629-36.
[49]	Instituto Nacional do Câncer José Alencar Gomes da Silva. (2014). Câncer de mama. Available in http://www2.inca.gov.br/wps/wcm/connect/tiposdecancer/site/home/mama
[50]	Rosas, M. S. L., Silva, B. N. M., Pinto, R. G. M. P., Silva, B. V., Silva, R. A., Guerra, L. R., Sores G. C. M. T., Castro, H. C., Lione V. O. F. (2013) Incidência do Câncer no Brasil e o Potencial Uso dos Derivados de Isatinas na Cancerologia Experimental. Rev. Virtual Quim 5 (2), 243-265.
[51]	Adorno, G. L. A. R. (2008) Angiogênese em carcinomas de mama: análise de expressão de fator de crescimento do endotélio vascular (VEGF) e suas correlações com outros fatores prognósticos. Dissertação. Universidade de Brasília 118f.
[52]	Dickson, R. B., Stancel, G. M. (2000) Estrogen receptor-mediated processes in normal and cancer cells. J. Natl. Cancer Inst. Monogr 27, 135-145.
[53]	Ettrich, B. G. (2011) Excesso de peso, adipocinas séricas e moléculas de adesão celular em mulheres com e sem câncer de mama. Dissertação. Universidade Federal do Rio Grande do Sul. 73f.
[54]	Tabak, D. (2014) Obesidade e o câncer. Revista Onco, march/april, 22-25.
[55]	Piovesan, A. C,. Soares, J. M. J., Mosquette, R., Simões, M. J., Simões, R. S., Baracat, E. C. (2005) Estudo morfológico e molecular da mama de ratas castradas tratadas com isoflavona ou estrogênios. Rev Bras Ginecol Obstet. 27 (4), 204-9.
[56]	Instituto Nacional de Câncer José de Alencar Gomes da Silva (Inca). (2014) Estimativa 2014 – Incidência de Câncer no Brasil. Ministério da Saúde 124f.
[57]	Garcia, M. G. M., Carvalho, M. G. F., Garcia, M. M. (1998) Análise dos fatores de risco em pacientes com adenocarcinoma endometrial. Reprodução & Climatério 13 (4), 232-236.
[58]	Ziel, H. K., Finkle, W. D. (1975) Increased risk of endometrial carcinoma among users of conjugated estrogens. N Engl J Med 293 (23), 1167-70.
[59]	Smith, D. C., Prentice, R., Thompson, D. J., Herrmann, W. L. (1975) Association of exogenous estrogen and endometrial carcinoma. N Engl J Med 293, 1164-7.
[60]	Grings, A. C., Kühne, J., Gomes, A. P., Jacobsen, T., Cascaes, A. C., Lara, G. M. (2009) Riscos e benefícios da terapia de reposição hormonal (TRH) em mulheres na menopausa. Rev. bras. anal. clin 41 (3), 231-234.
[61]	Grady, D., Gebretsadik, T., Kerlikowske, K., Ernster, V., Petotto, D. (1995) Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet & Gynecol 85 (2), 304-313.
[62]	Wannmacher, L., Lubianca, J. N. (2004) Terapia de reposição hormonal na menopausa: evidências atuais. Uso racional de medicamentos: temas selecionados 1 (6), 1-6.
[63]	Rozenberg, S., Vandromme, J., Antoine, C. (2013) Postmenopausal hormone therapy: risks and benefits. Nat Ver Endocrinol 9, 216-227.
[64]	Santos, L. O. M., Pessole, M. L., Ioshii, S. O. (2001) Efeito dos estrógenos conjugados e da Medroxiprogesterona sobre a mama. Revista brasileira de ginecologia e obstetrícia 23 (8), 23-35.
[65]	Hulley, S., Grady, D., Bush, T., Furberg, C., Herrington, D., Riggs, B., Vittinghoff, E. (1998) Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and estrogen/progestin replacement study (Hers) research group. Jama 280 (7), 605-613.
[66]	Carvalheira, J. B. C., Saad. M. J. A. (2006) Doenças associadas à resistência à insulina/hiperinsulinemia, não incluídas na síndrome metabólica. Arq Bras Endocrinol Metab 50 (2), 360-367.
[67]	Instituto Nacional do Câncer José Alencar Gomes da Silva. (2014) Síntese de Resultados e Comentários. Available in http://www.inca.gov.br/estimativa/2014/sintese-de-resultados-comentarios.asp
[68]	Hou, N., Hong, S., Wang, W., Olopade, O. I., Dignam, J. J., Huo, D. (2013) Hormone Replacement Therapy and Breast Cancer: Heterogeneous Risks by Race, Weight, and Breast Density. Journal of the National Cancer Institute 105(18), 1365-1372.
[69]	Albuquerque, A. M., Tocci, H. A. (2000) A polêmica associação entre a terapia de reposição hormonal e o risco de câncer de mama no climatério. Rev Enferm Unisa 1, 90-4.
[70]	Norman, A. W.. Litwack G. Hormones. 2ª Ed. 1997. Pg 558.
[71]	Steinberg, K. K.., Thacker, S. B., Smith, S. J., Stroup, D. F., Zack, M. M., Flanders, W. D., Berkelman, R. L. (1991) A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer. Jama 265, 1985-1989.
[72]	Marinho, R. M.. Fernandes, C.E. Wehba. S., Baracat, E. C. (2001) Projeto diretrizes: atenção primária e terapia de reposição hormonal no climatério. Federação brasileira das Sociedades de Ginecologia e Obstetrícia Pg 1- 11.
[73]	Lin, V. C-L., Jin, R., Tan, P-H., Aw, S-E., Woon, C-T., Bay, B-H. Progesterone Induces Cellular Differentiation in MDA-MB-231 Breast Cancer Cells Transfected with Progesterone Receptor Complementary DNA. American Journal of Pathology 162 (6), 1781- 1787.
[74]	Kendall, A., Dowsett, M., Folkerd, E., Smith., I. (2006) Caution: Vaginal estradiol appears to be contraindicated in postmenopausal women on adjuvant aromatase inhibitors. Ann Oncol 17 (4),584–7.
[75]	Dahir, M., Gustafson, D. T. (2014) Breast câncer, Aromatase Inhibitor Therapy, and Sexual Fuctioning: A pilot Study of the Effects of Vaginal Testosterone Therapy. Sex. Med 2 (1), 8-15.
[76]	Moegele, M., Buchholz, S., Seitz, S., Ortmann, O. (2012) Vaginal estrogen therapy in postmenopausal breast cancer patients treated with aromatase inhibitors. Arch Gynecol Obstet; 285 (5), 1397–402.
[77]	Antoine, C., Vandromme, J., Fastrez, M., Carly, B., Liebens, F., Rozenberg, S. (2008) A survey among breast cancer survivors: Treatment of the climacteric after breast cancer. Climacteric; 11 (4), 322–8.
[78]	Instituto Nacional do Câncer José Alencar Gomes da Silva. (2014). Colorretal. Available in http://www2.inca.gov.br/wps/wcm/connect/tiposdecancer/site/home/ovario
[79]	Fernandes, L. R. A., Lippi, U. G. and Baracat, F. F. (2003) Índice de Risco de Malignidade para Tumores do Ovário, Incorporando Idade, Ultra-sonografia e o CA-125. RBGO 25 (5), 345-351.
[80]	Fathalla, M. F. (1971) Incessant ovulation: a factor in ovarian neoplasia? The Lancet 298 (7716), 163.
[81]	Roskelley, C. D., Bissel, M. J. (2002) The dominance of the microenvironment in breast and ovarian cancer. Cancer Biol 12 (2), 97-104.
[82]	Rodriguez, C., et. al. (2001) Estrogen replacement therapy and ovarian cancer mortality in a large prospective study of US women. Jama 285 (11), 1460-1465.
[83]	Aquino, L. C. M., Andrade, F. H. F. M., Góes, C. A. M., Ribeiro, E. M. (2005) Aspectos genéticos do câncer de mama hereditário. Rev Soc Bras de Câncer 8, 44-8.
[84]	Leal, C. S., Santos, K. R.. R. A., Nunesmaia, H. G. S. (2002) Características epidemiológicas do câncer de mama no estado da Paraíba. Rev. Bras. De Matol 12 (2), 15-22.
[85]	Pinho, V. F. S., Coutinho, E. S. F. (2007) Variáveis associadas ao câncer de mama em usuárias de unidades básicas de saúde. Cad. Saúde Pública 23 (5), 1061-1069.
[86]	Anderson, A. S., Caswell, S. (2009) Obesity management--an opportunity for cancer prevention. Surgeon 7 (5), 282-285.
[87]	Anderson, K. E., Anderson, E., Mink, P. J., Hong, C. P. Kushi, L. H., Sellers, T. A., Lazovich, D., Folsom, A. R. (2001) Diabetes and endometrial cancer in the Iowa women's health study. Cancer Epidemiol Biomarkers Prev 10 (6), 611-6.
[88]	Safina, N. S., Urmancheeva, A. F., Tomilin, N. V., Krischen, O. V., Aksenov, N. L., Kazakov, V. I., Shramko, L. A. (2000) Parameters of lipid metabolism and polymorphism of apolipopretein a1 and angiotensin-converting enzyme genes in patients with endometrial carcinoma. Vopr Onkol 46 (1), 54-57.
[89]	Gonçalves, L. L. C., Lima, A. V., Brito, E. S., Oliveira, M. M., Oliveira, L. A. R., Abud, A. C. F., Daltro, A. S. T., Barros, A. M. M. S., Guimarães, U. V. (2010) Fatores de risco para câncer de mama em mulheres assistidas em ambulatório de oncologia. Rev. enferm 18 (3), 468-72.
[90]	McTiernan, A., Tworoger, S. S., Ulrich, C. M., Yasui, Y., Irwin, M. L., Rajan, K. B., Sorensen, B., Rudolph, R. E., Bowen, D., Stanczyk, F. Z., Potter, J. D., Schwartz, R. S. S. (2004) Effect of exercise on serum estrogens in postmenopausal women: a 12-month randomized clinical trial. Cancer Res 64 (8), 2923-8.

Cite This Article

Plain Text BibTeX RIS

APA Style

Thiele Osvaldt Rosales, Iara Patrícia Albrecht, Guilherme Barroso Langoni de Freitas. (2015). The Risk of Relationship between Hormonal Replacement Therapy and Cancer. Cancer Research Journal, 2(6-1), 49-56. https://doi.org/10.11648/j.crj.s.2014020601.16

Copy | Download

ACS Style

Thiele Osvaldt Rosales; Iara Patrícia Albrecht; Guilherme Barroso Langoni de Freitas. The Risk of Relationship between Hormonal Replacement Therapy and Cancer. Cancer Res. J. 2015, 2(6-1), 49-56. doi: 10.11648/j.crj.s.2014020601.16

Copy | Download

AMA Style

Thiele Osvaldt Rosales, Iara Patrícia Albrecht, Guilherme Barroso Langoni de Freitas. The Risk of Relationship between Hormonal Replacement Therapy and Cancer. Cancer Res J. 2015;2(6-1):49-56. doi: 10.11648/j.crj.s.2014020601.16

Copy | Download

@article{10.11648/j.crj.s.2014020601.16,
  author = {Thiele Osvaldt Rosales and Iara Patrícia Albrecht and Guilherme Barroso Langoni de Freitas},
  title = {The Risk of Relationship between Hormonal Replacement Therapy and Cancer},
  journal = {Cancer Research Journal},
  volume = {2},
  number = {6-1},
  pages = {49-56},
  doi = {10.11648/j.crj.s.2014020601.16},
  url = {https://doi.org/10.11648/j.crj.s.2014020601.16},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.crj.s.2014020601.16},
  abstract = {Menopause is an endocrine condition due to the decline in ovarian activity, which occurs in all women and is characterized as a progressive hypoestrogenism. To minimize damage from lack hormonal activity, hormone replacement therapy has been developed (TRH), which is widely used around the world, often without criteria pre-established. Thus, this study aims to identify hormonal therapies used postmenopausal and relate them to the development of tumors. In addition, identify the criteria for the use of HRT, the utilization time and women who are part of the risk groups are also objectives of this study. In the beginning, the clinical methodology of HRT included only estrogen, but epidemiological studies have observed that the progestin presence is essential in endometrial hyperplasia control adding to the therapy. Progestogens act depending on its molecular structure, and consequently selectivity, or may interact with other steroid receptors. From this interaction, different pharmacodynamic answers about importance in the development of tumors can be observed, ie, progesterone activity, estrogen, antiestrogen, androgen and / or antiandrogen. In view of the mechanism of carcinogen administration of estrogens, it can be said that HRT increases the risk of breast, uterus and ovary cancer. However, the estrogenic actions may be adjusted when there is administration of progestin drugs and with antiestrogenic and antiandrogenic actions. Given this, in menopausal women, it is advisable to trace gynecological cancer, before, during and after any therapeutic interventions, and the decision of using and the choice of HRT on an individual basis, through a careful assessment of signs and symptoms and long-term risk.},
 year = {2015}
}

Copy | Download

TY  - JOUR
T1  - The Risk of Relationship between Hormonal Replacement Therapy and Cancer
AU  - Thiele Osvaldt Rosales
AU  - Iara Patrícia Albrecht
AU  - Guilherme Barroso Langoni de Freitas
Y1  - 2015/01/27
PY  - 2015
N1  - https://doi.org/10.11648/j.crj.s.2014020601.16
DO  - 10.11648/j.crj.s.2014020601.16
T2  - Cancer Research Journal
JF  - Cancer Research Journal
JO  - Cancer Research Journal
SP  - 49
EP  - 56
PB  - Science Publishing Group
SN  - 2330-8214
UR  - https://doi.org/10.11648/j.crj.s.2014020601.16
AB  - Menopause is an endocrine condition due to the decline in ovarian activity, which occurs in all women and is characterized as a progressive hypoestrogenism. To minimize damage from lack hormonal activity, hormone replacement therapy has been developed (TRH), which is widely used around the world, often without criteria pre-established. Thus, this study aims to identify hormonal therapies used postmenopausal and relate them to the development of tumors. In addition, identify the criteria for the use of HRT, the utilization time and women who are part of the risk groups are also objectives of this study. In the beginning, the clinical methodology of HRT included only estrogen, but epidemiological studies have observed that the progestin presence is essential in endometrial hyperplasia control adding to the therapy. Progestogens act depending on its molecular structure, and consequently selectivity, or may interact with other steroid receptors. From this interaction, different pharmacodynamic answers about importance in the development of tumors can be observed, ie, progesterone activity, estrogen, antiestrogen, androgen and / or antiandrogen. In view of the mechanism of carcinogen administration of estrogens, it can be said that HRT increases the risk of breast, uterus and ovary cancer. However, the estrogenic actions may be adjusted when there is administration of progestin drugs and with antiestrogenic and antiandrogenic actions. Given this, in menopausal women, it is advisable to trace gynecological cancer, before, during and after any therapeutic interventions, and the decision of using and the choice of HRT on an individual basis, through a careful assessment of signs and symptoms and long-term risk.
VL  - 2
IS  - 6-1
ER  -

Copy | Download

Author Information

Thiele Osvaldt Rosales

Department of Pharmacy, State University of Center-West, Guarapuava, Parana, Brazil
Iara Patrícia Albrecht

Department of Pharmacy, State University of Center-West, Guarapuava, Parana, Brazil
Guilherme Barroso Langoni de Freitas

Department of Pharmacy, State University of Center-West, Guarapuava, Parana, Brazil; Post-Degree Program in Internal Medicine and Health Sciences at UFPR, Department of Clinical Patology, Federal University of Parana, Curitiba, Parana, Brazil

Download PDF

Sections

Plain Text BibTeX RIS

APA Style

Thiele Osvaldt Rosales, Iara Patrícia Albrecht, Guilherme Barroso Langoni de Freitas. (2015). The Risk of Relationship between Hormonal Replacement Therapy and Cancer. Cancer Research Journal, 2(6-1), 49-56. https://doi.org/10.11648/j.crj.s.2014020601.16

Copy | Download

ACS Style

Thiele Osvaldt Rosales; Iara Patrícia Albrecht; Guilherme Barroso Langoni de Freitas. The Risk of Relationship between Hormonal Replacement Therapy and Cancer. Cancer Res. J. 2015, 2(6-1), 49-56. doi: 10.11648/j.crj.s.2014020601.16

Copy | Download

AMA Style

Thiele Osvaldt Rosales, Iara Patrícia Albrecht, Guilherme Barroso Langoni de Freitas. The Risk of Relationship between Hormonal Replacement Therapy and Cancer. Cancer Res J. 2015;2(6-1):49-56. doi: 10.11648/j.crj.s.2014020601.16

Copy | Download

@article{10.11648/j.crj.s.2014020601.16,
  author = {Thiele Osvaldt Rosales and Iara Patrícia Albrecht and Guilherme Barroso Langoni de Freitas},
  title = {The Risk of Relationship between Hormonal Replacement Therapy and Cancer},
  journal = {Cancer Research Journal},
  volume = {2},
  number = {6-1},
  pages = {49-56},
  doi = {10.11648/j.crj.s.2014020601.16},
  url = {https://doi.org/10.11648/j.crj.s.2014020601.16},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.crj.s.2014020601.16},
  abstract = {Menopause is an endocrine condition due to the decline in ovarian activity, which occurs in all women and is characterized as a progressive hypoestrogenism. To minimize damage from lack hormonal activity, hormone replacement therapy has been developed (TRH), which is widely used around the world, often without criteria pre-established. Thus, this study aims to identify hormonal therapies used postmenopausal and relate them to the development of tumors. In addition, identify the criteria for the use of HRT, the utilization time and women who are part of the risk groups are also objectives of this study. In the beginning, the clinical methodology of HRT included only estrogen, but epidemiological studies have observed that the progestin presence is essential in endometrial hyperplasia control adding to the therapy. Progestogens act depending on its molecular structure, and consequently selectivity, or may interact with other steroid receptors. From this interaction, different pharmacodynamic answers about importance in the development of tumors can be observed, ie, progesterone activity, estrogen, antiestrogen, androgen and / or antiandrogen. In view of the mechanism of carcinogen administration of estrogens, it can be said that HRT increases the risk of breast, uterus and ovary cancer. However, the estrogenic actions may be adjusted when there is administration of progestin drugs and with antiestrogenic and antiandrogenic actions. Given this, in menopausal women, it is advisable to trace gynecological cancer, before, during and after any therapeutic interventions, and the decision of using and the choice of HRT on an individual basis, through a careful assessment of signs and symptoms and long-term risk.},
 year = {2015}
}

Copy | Download

TY  - JOUR
T1  - The Risk of Relationship between Hormonal Replacement Therapy and Cancer
AU  - Thiele Osvaldt Rosales
AU  - Iara Patrícia Albrecht
AU  - Guilherme Barroso Langoni de Freitas
Y1  - 2015/01/27
PY  - 2015
N1  - https://doi.org/10.11648/j.crj.s.2014020601.16
DO  - 10.11648/j.crj.s.2014020601.16
T2  - Cancer Research Journal
JF  - Cancer Research Journal
JO  - Cancer Research Journal
SP  - 49
EP  - 56
PB  - Science Publishing Group
SN  - 2330-8214
UR  - https://doi.org/10.11648/j.crj.s.2014020601.16
AB  - Menopause is an endocrine condition due to the decline in ovarian activity, which occurs in all women and is characterized as a progressive hypoestrogenism. To minimize damage from lack hormonal activity, hormone replacement therapy has been developed (TRH), which is widely used around the world, often without criteria pre-established. Thus, this study aims to identify hormonal therapies used postmenopausal and relate them to the development of tumors. In addition, identify the criteria for the use of HRT, the utilization time and women who are part of the risk groups are also objectives of this study. In the beginning, the clinical methodology of HRT included only estrogen, but epidemiological studies have observed that the progestin presence is essential in endometrial hyperplasia control adding to the therapy. Progestogens act depending on its molecular structure, and consequently selectivity, or may interact with other steroid receptors. From this interaction, different pharmacodynamic answers about importance in the development of tumors can be observed, ie, progesterone activity, estrogen, antiestrogen, androgen and / or antiandrogen. In view of the mechanism of carcinogen administration of estrogens, it can be said that HRT increases the risk of breast, uterus and ovary cancer. However, the estrogenic actions may be adjusted when there is administration of progestin drugs and with antiestrogenic and antiandrogenic actions. Given this, in menopausal women, it is advisable to trace gynecological cancer, before, during and after any therapeutic interventions, and the decision of using and the choice of HRT on an individual basis, through a careful assessment of signs and symptoms and long-term risk.
VL  - 2
IS  - 6-1
ER  -

Copy | Download